Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

100.84 -7.05 (-6.53%)
Streaming Delayed Price Updated: 12:19 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Otonomy Shares Dipped By Around 54%; Here Are 67 Biggest Movers From Yesterday
Gainers Nutex Health Inc. (NASDAQ: NUTX) jumped 72.4% to settle at $0.9551 on Thursday. Nutex Health recently provided a corporate update. 
Via Benzinga
Better Buy: Moderna vs. Axsome Therapeutics
Both of these biotechs offer exciting future prospects. 
Via The Motley Fool
Axsome Therapeutics' Sunosi Improves Cognitive Function In Patients With Sleep Disorder
Via Benzinga
Albertsons Companies, Domino's Pizza And Other Big Gainers From Thursday
U.S. stocks closed higher on Thursday, with the Dow Jones jumping over 800 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
COLA 2023: How Much Did Social Security Benefits Increase for 2023?
Social Security is increasing for 2023 as the Social Security Administration announces an update to the Cost-of-Living Adjustment (COLA). 
Via InvestorPlace
Why Is Axsome Therapeutics (AXSM) Stock Up Today?
Sometimes, company shares can catch a bid when a rival gets bad news. That's happening with Axsome today as AXSM stock moves higher. 
Via InvestorPlace
Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges
The company noted "paradoxical results" where the placebo, at times, topped the drug. 
Via Investor's Business Daily
Why Relmada Therapeutics Shares Are Trading Lower By 84%; Here Are 23 Stocks Moving Premarket
Gainers Laser Photonics Corporation (NASDAQ: LASE) shares rose 45% to $4.24 in pre-market trading. Laser Photonics announced that Coca-Cola recently completed the implementation of its first CleanTech... 
Via Benzinga
8 Analysts Have This to Say About Axsome Therapeutics
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter: 
Via Benzinga
Why Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers FedNat Holding Company (NASDAQ: FNHC) shares jumped 89% to $0.4242 after dipping 34% on Wednesday. 
Via Benzinga
Delta Air Lines, Walgreens Boots Alliance And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
3 Red-Hot Stocks That Could Continue to Beat the Market
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
Mizuho Bolsters Price Target By 55% On This Migraine Stock
Via Benzinga
Got $1,000? These 3 Stocks Could Double Your Money in 5 Years.
All three stocks are worth keeping a lot longer than half a decade. 
Via The Motley Fool
Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold
Vertex already generates billions in revenue -- but there may be more to come. 
Via The Motley Fool
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
From Axsome Therapeutics, Inc.
Via GlobeNewswire
These 7 Biotech Stocks Are Set to Boom in 2023
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
If You Invested $5,000 in Axsome Therapeutics in 2019, This Is How Much You Would Have Today
Could the stock keep performing? 
Via The Motley Fool
Jim Cramer On This Industrial Stock: 'You Don't Know What's In It'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Sociedad Quimica y Minera de Chile (NYSE: SQM) as "fertilizer’s in short supply and so is lithium." 
Via Benzinga
3 Stocks Savvy Investors Are Buying Hand Over Fist
These high-flying stocks are defying the bear market. 
Via The Motley Fool
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
From Axsome Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets
7 Top-Rated Biotech Stocks to Buy for Q4
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
Via InvestorPlace
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks. 
Via InvestorPlace
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Axsome Therapeutics Commences Late-Stage Migraine Study
Axsome Therapeutics (NASDAQ: AXSM) has enrolled the first patient in the EMERGE trial of its lead candidate AXS-07 for the acute treatment of migraine. 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS